Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study

Published Date: 14 Jun 2024

Second-gen ALK inhibitor induces high response rate, associated with impressive survival

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Novel Anti-CD38 Drug Shows Promise for Immune Thrombocytopenia

2.

Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study

3.

Climate change is expected to increase the number of suicide deaths

4.

Cancer care crowdfunding increasingly common, but rarely successful

5.

Using AI, one can find cancer risk factors.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot